We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Alzheimer’s drug

News List

Amgen and Novartis discontinue Alzheimer’s drug development programme pharmaceutical-technology
July 17, 2019
Amgen and Novartis have announced the discontinuation of their clinical development programme for CNP520 (umibecestat), a BACE1 inhibitor for Alzheimer’s disease, which the Arizona-based Banner Alzheimer’s Institute was also supporting.
Lilly teams up with AC Immune for Alzheimer’s drug pharmaceutical-technology
December 14, 2018
Eli Lilly has signed a licence and collaboration agreement with Swiss biotech AC Immune for the research and development of tau aggregation inhibitor small molecules.....
Biogen’s Alzheimer’s drug succeeds in trial biospectrumasia
July 09, 2018
The study achieved statistical significance on key predefined endpoints evaluating efficacy at 18 months on slowing progression in Alzheimer's Disease Composite Score (ADCOMS) and on reduction of amyloid accumulated in the brain as measured using amyloid-
Alzheimer’s drug prescribed ‘off-label’ for mild cognitive impairment could pose risk for some firstwordpharma
February 27, 2017
Donepezil, a medication that is approved to treat people with Alzheimer’s disease, should not be prescribed for people with mild cognitive impairment without a genetic test.